地红霉素对肺炎衣原体的体外活性

In-vitro activity of dirithromycin against Chlamydia pneumoniae.

作者信息

Roblin P M, Kutlin A, Sokolovskaya N, Hammerschlag M R

机构信息

Department of Pediatrics, State University of New York, Health Science Center at Brooklyn, 11203, USA.

出版信息

J Antimicrob Chemother. 1997 May;39(5):647-9. doi: 10.1093/jac/39.5.647.

DOI:10.1093/jac/39.5.647

PMID:9184366

Abstract

The in-vitro susceptibilities of 12 strains of Chlamydia pneumoniae were determined for dirithromycin, a new macrolide antibiotic, erythromycyclamine, its active metabolite, and erythromycin. Both dirithromycin and erythromycyclamine had an MIC90 of 2 mg/L, as compared with 0.062 mg/L for erythromycin. The combination of dirithromycin and erythromycyclamine appeared to be additive. Determination of the role of dirithromycin for the treatment of C. pneumoniae infection will depend on the results of prospective, controlled studies utilizing culture.

摘要

测定了12株肺炎衣原体对新型大环内酯类抗生素地红霉素、其活性代谢产物红霉环素以及红霉素的体外敏感性。地红霉素和红霉环素的MIC90均为2mg/L，而红霉素的MIC90为0.062mg/L。地红霉素与红霉环素联合使用似乎具有相加作用。地红霉素在治疗肺炎衣原体感染中作用的确定将取决于采用培养法的前瞻性对照研究结果。